Form 4: Adicet Bio CFO Granted 43,361 Stock Options

Adicet Bio's Chief Financial Officer, Brian Nicholas Harvey, was granted 43,361 stock options with an exercise price of $6.81.

Summary

• Brian Nicholas Harvey, Chief Financial Officer of Adicet Bio, Inc. (ACET), was granted stock options on March 25, 2026.
• A total of 43,361 stock options were granted, each with an exercise price of $6.81.
• The options will vest monthly over a four-year period, with 1/48th vesting on each monthly anniversary of the grant date.
• Vesting is contingent upon the CFO maintaining a service relationship with Adicet Bio.
• The granted stock options are set to expire on March 24, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard and generally positive event, indicating executive retention and alignment of interests, without significant new financial or operational news.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with long-term shareholder value creation.
• The four-year vesting schedule incentivizes the retention of a key executive within the company.

Risks

• The value of the stock options is directly tied to Adicet Bio's future stock performance; if the stock price does not exceed the $6.81 exercise price, the options may hold no intrinsic value.
• Should the Chief Financial Officer's service relationship with the Issuer terminate before full vesting, a portion of the unvested options will be forfeited.

Future Outlook

The granting of these stock options indicates a long-term commitment to the Chief Financial Officer and reflects an expectation of future company growth that would enhance the value of these options.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock options, is a standard practice in the biotechnology sector to attract, retain, and incentivize key executives. This approach aligns executive performance with the company's long-term strategic goals and shareholder interests, particularly common in growth-oriented companies like Adicet Bio.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech industry frequently include a combination of stock options and restricted stock units (RSUs).
• The 48-month vesting schedule is a common industry standard for executive equity grants, designed to foster long-term commitment and retention.
• Setting the exercise price at the market price on the grant date is a typical practice for incentive stock options across various sectors.

Related Party Transactions

• The grant of stock options to the Chief Financial Officer constitutes a related party transaction, which is a standard form of executive compensation and is transparently reported via this Form 4 filing.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, balanced by increased executive motivation and alignment with long-term value creation.
• Employees: No direct impact on other employees is mentioned in this filing.

Next Steps

• The Chief Financial Officer will continue to vest options monthly over the next four years, contingent on continued employment.
• The Chief Financial Officer may choose to exercise vested options at any point before the expiration date of March 24, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a key executive. While it signals continued executive commitment, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard insider transaction.

Keywords

Adicet Bio, ACET, Stock Option, CFO, Equity Compensation, Insider Transaction, Form 4, Beneficial Ownership